Wyeth Ends Temsirolimus Breast Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm cites inadequate efficacy results from an interim analysis of a Phase III breast cancer trial; other oncology trials for temsirolimus are ongoing.